Red Flags Detected
- Going Concern (new) — Company disclosed substantial doubt about ability to continue as going concern due to insufficient liquidity beyond one year without additional capital or sufficient commercial sales.
- Delisting (new) — Company received formal Nasdaq delisting notice due to stock price falling below $1.00 for 30 consecutive business days; has until November 2, 2026 to regain compliance.
- Securities Litigation (removed) — Securities litigation previously disclosed in detail is now referenced only in notes rather than in main legal proceedings section.
Humacyte faces Nasdaq delisting notice, going-concern doubt as Q1 revenue hits $0.5M
Filed May 13, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~2 min read
Key Changes
-
high
Company disclosed substantial doubt about ability to continue as going concern, stating it lacks sufficient liquidity to fund operations beyond one year without additional capital or sufficient commercial sales.
MD&A: Liquidity verify on EDGAR → -
high
Received Nasdaq delisting notice May 4, 2026 after stock closed below $1.00 for 30 consecutive days; has until November 2, 2026 to regain compliance by maintaining $1.00+ bid for 10 consecutive days.
Risk Factors verify on EDGAR → -
high
Implemented second workforce reduction in 13 months, cutting 45 employees in May 2026 (vs. 31 in April 2025) with $0.8M severance charges and $14.3M expected net savings through year-end.
MD&A: Workforce Reduction verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.
Partner
Trade HUMAW commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 10, 2026 9:46 PM